secwatch.observer — SEC 8-K summary
======================================

Issuer:     Bausch Health Companies Inc. (BHC)
CIK:        0000885590
Form:       8-K
Filed at:   2026-01-23T23:59:59+00:00
Accession:  0000885590-26-000008
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bausch Health issues press release on Phase 3 RED-C trial; no details in filing text
--------------------------------------------------------------------------------

- Press release announces results of global Phase 3 RED-C program for amorphous-rifaximin in liver cirrhosis.
- Trial evaluated primary prevention of hepatic encephalopathy; specific endpoint outcomes not provided in filing summary.
- Filing includes only the 8-K body; the attached Exhibit 99.1 text was not included for analysis.
- Item 7.01 Regulation FD disclosure; information is furnished, not filed, per standard practice.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/885590/000088559026000008/0000885590-26-000008-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/885590/000088559026000008/bhc-20260123.htm
  HTML page:      https://secwatch.observer/filing/0000885590-26-000008

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer